More than $35 billion! 278 pharmaceutical companies research and development investment exposure East Sunshine drug surge of 500%

In recent times, listed companies have issued interim results report, according to incomplete statistics, 278 A-shares and Hong Kong-listed pharmaceutical companies disclosed the 2020 H1 research and development investment, a total amount of more than 35 billion yuan.
120 pharmaceutical companies invested more than 50 million yuan in research and development, of which 5 pharmaceutical companies more than 1 billion (compared with 4 in the same period last year);
table: in the first half of 2020 research and development investment of more than 50 million listed pharmaceutical companies note: table is incomplete statistics; Five pharmaceutical companies invested more than 50 million yuan in research and development in the first half of the year, with a total amount of more than 30 billion yuan, of which 68 pharmaceutical companies invested more than 100 million yuan in research and development (compared with 52 in the same period last year), and Baiji Shenzhou, China Biopharmaceuticals, Hengrui Pharmaceuticals, Fosun Pharma, Shi Pharmaceutical Group ranked top 5, with more than 1 billion yuan invested in research and development, and more than 10% of revenue.
spending on research and development in Shenzhou was US$590 million (about 4 billion yuan), an increase of 44.99 percent over the same period last year, accounting for 501.27 percent of operating income.
the end of the reporting period, there were more than 1,350 clinical development teams worldwide, conducting or planning 70 clinical trials.
class 1 new drug developed by the Company, reilly-pearl monoanti-injections (PD-1), Zebtini capsules (BTK inhibitors) have been approved for the market, and Parmpali capsules (PARP1 and PARP) have been approved for the market 2 inhibitors) has been declared on the market, BGB-283 capsules (RAF inhibitors) completed Phase I clinical, BGB-3245-MBP capsules, BGB-A333 injections, etc. approved clinical.
,863 million yuan in research and development, an increase of 25.56 percent over the same period last year, accounting for 16.49 percent of operating income.
reporting period, the company obtained 3 batch of innovative pharmaceutical production, 1 batch of generic drug production, 37 clinical approval of innovative drug;
The company currently has more than 3400 people of research and development team, innovative drugs Aresib, Apatini, thiopental non-gesting, pyridoxine, carelli pearl monoanti, toluene sulphate rhemazolon has been approved for listing, the future basic formation of each year have innovative drugs applied for clinical, every 1-2 years there is a benign development trend of innovative drugs on the market.
invested 1,689 million yuan in research and development, an increase of 25.02 percent over the same period last year, accounting for 12.06 percent of operating income.
reporting period, the company introduced the innovative drug AvalancoPa tablets were approved for the market, FKC876 (CAR-T products) declared on the market, 12 generic drugs were approved by the FDA for listing.
By the end of the reporting period, the company had nearly 2,300 research and development personnel, and had 248 projects in the research and evaluation of innovative drugs, generic drugs, biosimilars and consistency evaluation, including 17 small molecule innovative drugs, 2 modified new drugs, 21 bio-innovative drugs, 21 biosimilars, generic drugs. 117, 46 consistent evaluation projects, 2 Chinese medicine; 6 projects are in the process of declaring clinical trials, 33 projects are undergoing clinical trials, 34 projects are awaiting approval and listing, 23 products have passed the consistent evaluation; and a total of 22 projects have been introduced, of which 9 are imported innovative drugs and 13 are imported generic drugs.
1,541 million yuan, down 5.23 percent from a year earlier, accounting for 12.18 percent of operating income.
reporting period, the company obtained 12 production approvals, 22 clinical approvals, 9 varieties of evaluation (including the same evaluation), 19 declared production, 29 declared clinical, new declaration consistency evaluation 4.
Up to now, the company's cumulative clinical approval, clinical trials and declared production of a total of 438 products in research, including 38 drugs for liver disease, 189 anti-tumor drugs, 22 respiratory drugs, 24 endocrine drugs, 35 cardiovascular drugs and other types of drugs 130.
1,452 million yuan, an increase of 54.24 percent over the same period last year, accounting for 11.54 percent of operating income.
reporting period, the company obtained 9 drug registration approvals, 5 clinical approvals, 12 varieties (18 product regulations) through consistent evaluation, 1 generic drug approved by the FDA for listing, 1 new drug preparation improvement application for listing.
by the end of the reporting period, the company's research and development team of more than 2000 people, in the research project more than 300 items, including small molecule innovation drugs more than 40 items, large molecule innovation drugs more than 50 items, more than 20 new preparations; During the review-pending phase, 42 products are undergoing clinical trials (31 innovative drugs, 11 new preparations), 9 products are undergoing bioexuality trials, and 7 products are in clinical approval (6 domestic and 1 United States).
Nearly 80% of pharmaceutical companies increased investment in research and development, these seven year-on-year growth of more than 100% in 2020 outbreak of new crown pneumonia affected the economic growth of all industries, the pharmaceutical industry is not immune, but there are still most pharmaceutical companies continue to increase investment in research and development.
120 pharmaceutical companies that invested 50 million yuan in research and development in the first half of 2020, 94 showed positive growth in research and development investment compared with the same period last year, accounting for nearly 80%.
companies with more than 100% year-on-year investment in research and development, including Dongsian Pharmaceuticals (500.60%), Yongtai Bio-B (306.1%), Xiang Xue Pharmaceuticals (294.06%), No. Cheng Jianhua-B (143.88%), Corning Jerry Pharmaceuticals-B (139.86%), Hainan Hai Medicine (120.61%), Wanfu Bio (116.95%).
Invested 685 million yuan in research and development, an increase of 500.6 percent over the same period last year, accounting for 32.86 percent of operating income. during the
reporting period, the company's first biological recombinant human insulin injection was approved for market, three generics were approved for production, and another 10-12 varieties are expected to be approved for listing this year;
As of the end of the reporting period, class 1 new drug phosphate emitavir (NS5A inhibitors) was declared on the market and is expected to be approved in the second half of 2020;
meters intranet data show that at present, Dongsian medicine in the research of new drugs (excluding raw materials and listed varieties) more than 30, of which 1 new class of drugs more than 20.
193 million yuan in research and development, an increase of 294.06 percent over the same period last year, accounting for 10.65 percent of operating income.
company's main business for modern Chinese medicine and Chinese medicine tablets research and development, production and sales, in recent years gradually involved in the research and development of chemical drugs.
the end of the reporting period, the company's new class 1 drug KX02 tablets, TAEST16001 injections are being carried out phase I clinical, STP705 is in the process of clinical preparation for phase I.
-B research and development costs of 231 million yuan, an increase of 143.88 percent over the same period last year, no products have yet been commercialized.
the reporting period, the first class 1 new drug, Aoptinib (BTK inhibitor), submitted two applications for listing of the new drug (relapsed CLL/SLL and MRL).
at the end of the reporting period, the company employed 287 people, 173 of whom were research and developers, and in the study of new class 1 drugs, ICP-192 (pan-FGFR inhibitors) were conducting Phase II clinical, ICP-105 (FGFR4 inhibitors) In Phase I clinical, ICP-723 (TRK inhibitors) was approved clinically, ICP-332 (TYK2 inhibitors), ICP-189 (SHP2 variant inhibitors), ICP-490, etc. are in the IND preparation stage.
42 pharmaceutical companies accounted for 10% of revenue and above, 10 of the 5 more than 100% of 120 pharmaceutical companies have not yet commercialized their products, 42 pharmaceutical companies have more than 10% of their operating income, Dongdao Pharmaceuticals-B (762) .28%), Baotai (501.35%), Baiji Shenzhou (501.27%), Goliath Pharmaceuticals-B (162.51%), Junshi Bio (123.30%) 5 pharmaceutical companies exceeded 100%.
245 million yuan, a decrease of 30.51 percent from the same period last year, accounting for 501.35 percent of revenue.
at the end of the reporting period, the company's research and development team of 249 people, 1 product approved production (BAT1406), for the first domestic Adami single anti-biosychable drugs, in the first half of 2020 to achieve sales revenue of 0.49 billion yuan; Twenty-three products are under study, two have submitted applications for listing (innovative drug BAT2094, biosynthic drug BAT1706), and three are in Phase III clinical phase (BAT1806, BAT2506, BAT8001).
709 million yuan, an increase of 92.00 percent over the same period last year, accounting for 123.30 percent of revenue.
reporting period, JS001 (Triple Monoanti) is conducting 15 key registered clinical trials (2 have submitted NDA applications), the country's first new coronavirus and antibody JS016 (recombinant all-human source anti-SARS-CoV-2 monoantigen injection) into Phase I clinical, TAB004/JS004 (BTLA monoantigen) approved clinical.
By the end of the reporting period, the company was working on 21 products (19 innovative drugs, 2 biosypolitic drugs), covering malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases and infectious diseases, of which UDP1213 (Adamo monobiotic drugs) has been applied for market.
: Oriental Wealth Network, listed companies annual report Note: data statistics as of September 8, pure manual finishing, if there are omissions, welcome to point out!